{"prompt": "['CONFIDENTIAL', 'Protocol ANB019-002 - Amendment 5', 'Table 1', 'Study Treatment Details', 'Study Treatment Name:', 'ANB019', '(anti-interleukin-36 receptor [IL-36R] monoclonal antibody)', 'Dosage Formulation:', 'The drug product is formulated as', 'Study Treatment Description', 'ANB019 drug product is a sterile, clear to slightly opalescent and', 'colorless to yellow solution supplied in a single-use, 2R, Type', 'I', 'glass vial with a', 'Unit Dose Strength(s)/Dosage Level(s):', 'A dose of 750 mg.', 'intravenously (IV) followed by 3 doses', 'of 100 mg/mL subcutaneously (SC) administered on Days 29, 57,', 'and 85.', 'Route of Administration', 'IV infusion (1 dose) and SC injections (3 doses).', 'Dosing Instructions:', 'ANB019 will be administered to subjects by IV infusion in', 'polyvinyl chloride or polyolefin bags following dilution to a total', 'volume of', 'with sterile normal saline (0.9% NaCl).', 'Infusions will be administered over', 'The infusion may be', 'slowed or interrupted for subjects experiencing infusion-related', 'AEs.', 'For SC injections, ANB019 should be prepared by drawing up the', 'required dosing volume into suitable sized syringe and attaching a', 'dosing needle. No further dilution is required. Subjects receiving', 'ANB019 will receive', '(100 mg) SC injection. The injections', 'should be rotated with each dose and should not be given into', 'moles, scars, tattoos or areas where the skin is tender, bruised, red,', 'hard, or not intact. Abdominal administration is the preferred site', 'for SC doses.', '6.2', 'reparation/Handling/Storage/Accountability', '1. The Investigator or designee must confirm appropriate temperature conditions have', 'been maintained during transit for all study treatment received and any discrepancies', 'are reported and resolved before use of the study treatment.', '2. Only subjects enrolled in the study may receive study treatment and only authorized', 'study center staff may supply or administer study treatment. All study treatments must', 'be stored in a secure, environmentally controlled, and monitored (manual or', 'automated) area in accordance with the labeled storage conditions with access limited', 'to the Investigator and authorized study center staff.', '3. ANB019 vials must be refrigerated at 2\u00b0C to 8\u00b0C (36\u00b0F to 46\u00b0F) until the day of use.', 'ANB019 should not be used beyond the re-test or expiration date provided by the', 'manufacturer. Vial contents should not be frozen or shaken. ANB019 vials may be', 'stored at room temperature (8\u00b0C to 25\u00b0C [46\u00b0F to 77\u00b0F]) in a diluted or undiluted state', 'for up to a maximum of', '.', 'Once ANB019 has been diluted with sterile 0.9%', 'NaCl, the solution may be stored at room temperature (8\u00b0C to 25\u00b0C [46\u00b0F to 77\u00b0F]) for', '29 October 2019', '33']['CONFIDENTIAL', 'Protocol ANB019-002 - Amendment 5', 'up to', 'Vials are intended for single-use only; therefore, any remaining solution', 'should be discarded.', '4. The Investigator, institution, or the head of the medical institution (where applicable)', 'is responsible for study treatment accountability, reconciliation, and record', 'maintenance (ie, receipt, reconciliation, and final disposition records).', '5. Further guidance and information for the final disposition of unused study treatment', 'are provided in the Pharmacy Manual.', 'The Investigator, a member of the study center staff, or a hospital pharmacist must maintain an', 'adequate record of the receipt and distribution of all study drug using the Drug Accountability', 'Form. These forms must be available for inspection at any time.', '6.3', 'Measures to Minimize Bias: Randomization and Blinding', 'This section is not applicable as this is an open-label study.', '6.4', 'Study Treatment Compliance', 'The prescribed dosage, timing, and mode of administration may not be changed except in cases', 'of infusion-related AEs, the study drug administration may be slowed or interrupted. Any', 'departures from the intended regimen must be recorded in the electronic case report forms', \"(eCRFs). Infusion start date/time and infusion end date/time will be documented in the subject's\", 'eCRF. Any infusion interruptions (stop date/time and restart date/time), changes in infusion rate,', \"and/or incomplete dose administration will also be documented in the subject's eCRF.\", '6.5', 'Concomitant Therapy', 'Any medication or vaccine (including over-the-counter or prescription medicines, vitamins,', 'and/or herbal supplements) that the subject is receiving at the time of enrollment and receives', 'during the study must be recorded on the eCRF along with:', 'Reason for use.', 'Dates of administration including start and end dates.', 'Dosage information including dose and frequency.', 'In addition, all prior medications used to treat GPP disease conditions and any other medications', 'taken within 6 months prior to enrollment must be recorded in the eCRF. The concomitant', 'treatments for other indications that are not listed in the prohibited medication section must be on', 'a stable dose for at least 4 weeks before study treatment administration. Dose adjustments of', 'these treatments should be avoided during the study.', 'The Medical Monitor should be contacted if there are any questions regarding concomitant or', 'prior therapy.', 'Treatment with bland emollients (without pharmacological active ingredients) will be permitted', 'throughout the trial, except within 24 hours prior to the study visits.', '29 October 2019', '34']\n\n###\n\n", "completion": "END"}